Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alexandria Real Estate Equities Inc (ARE) vs Merck & Co., Inc. (MRK) Price & Performance

Alexandria Real Estate Equities IncTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Alexandria Real Estate Equities Inc vs Merck & Co., Inc. — how do they compare? Alexandria Real Estate Equities Inc trades at $48.5 (market cap $8.32B), while Merck & Co., Inc. trades at $130.38 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 38.8× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays the higher dividend (5.96%). Which is the better fit depends on your goals.

AREMRK
Market Cap
$8.32B$323.00B
Sector
Real EstateHealth
52-Week High
$87.45$131.84
52-Week Low
$40.41$77.60
Enterprise Value
$21.02B$369.77B
Dividend Yield
5.96%2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alexandria Real Estate Equities Inc

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.

The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.

Read more on ARE

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK